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Exposure-Response Model of Subcutaneous C1-Inhibitor
Concentrate to Estimate the Risk of Attacks in Patients
With Hereditary Angioedema
Ying Zhang1*, Michael A. Tortorici 1, Dipti Pawaskar1, Ingo Pragst2, Thomas Machnig3, Matthew Hutmacher4, Bruce Zuraw5,
Marco Cicardi6, Timothy Craig7, Hilary Longhurst8 and Jagdev Sidhu9
Subcutaneous C1-inhibitor (HAEGARDA, CSL Behring), is a US Food and Drug Administration (FDA)-approved, highly
concentrated formulation of a plasma-derived C1-esterase inhibitor (C1-INH), which, in the phase III Clinical Studies for
Optimal Management in Preventing Angioedema with Low-Volume Subcutaneous C1-inhibitor Replacement Therapy
(COMPACT) trial, reduced the incidence of hereditary angioedema (HAE) attacks when given prophylactically. Data from the
COMPACT trial were used to develop a repeated time-to-event model to characterize the timing and frequency of HAE attacks
as a function of C1-INH activity, and then develop an exposure–response model to assess the relationship between C1-INH
functional activity levels (C1-INH(f)) and the risk of an attack. The C1-INH(f) values of 33.1%, 40.3%, and 63.1% were predicted
to correspond with 50%, 70%, and 90% reductions in the HAE attack risk, respectively, relative to no therapy. Based on trough
C1-INH(f) values for the 40 IU/kg (40.2%) and 60 IU/kg (48.0%) C1-INH (SC) doses, the model predicted that 50% and 67% of the
population, respectively, would see at least a 70% decrease in the risk of an attack.
CPT Pharmacometrics Syst. Pharmacol. (2018) 00, 00; doi:10.1002/psp4.12271; published online on 0 Month 2018.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 Administration of the FDA-approved C1-INH (SC;
HAEGARDA) leads to dose-dependent, physiologically
relevant increases in trough C1-INH(f) in patients with
HAE.
WHAT QUESTION DID THIS STUDY ADDRESS?
 The relationship of exposure of C1-INH (SC) to the
risk of breakthrough HAE attacks, and whether different
patient factors influence this relationship.
WHAT DOES THIS STUDY ADD TO OUR
KNOWLEDGE?
 A strong, inverse exposure–response relationship
was shown between C1-INH(f) and breakthrough HAE
attacks; the effect of C1-INH (SC) on the reduction in
risk was not age dependent. The 40 and 60 IU/kg C1-
INH (SC) doses are predicted to increase trough C1-
INH(f) levels well above the clinically significant 40%
threshold.
HOW MIGHT THIS CHANGE DRUG DISCOVERY,
DEVELOPMENT, AND/OR THERAPEUTICS?
 The link between C1-INH(f) and the risk of an attack
substantiates the C1-INH dose used for HAE prophy-
laxis and will inform future studies aimed at optimizing
outcomes on replacement therapy. A large proportion
of patients treated with C1-INH (SC) should be
expected to experience notable reductions in the rela-
tive risk of an HAE attack.
Hereditary angioedema (HAE) is a rare, debilitating, and
potentially life-threatening genetic disease caused by a defi-
ciency in functional C1-esterase inhibitor (C1-INH).1,2 Muta-
tions in the C1-INH gene result in two types of HAE due to
C1-INH deficiency or dysfunction and can be detected by
abnormal complement protein levels: type I patients (85% of
cases) have low levels of C1-INH antigen in plasma; type II
patients (15% of cases) have low levels of functional C1-INH
protein and normal or slightly elevated levels of C1-INH anti-
gen. C1-INH(f) assays are based on the principle of C1-INH
in the samples inhibiting a certain volume of C1-esterase.
Outputs are expressed as a percentage of functional activity
in normal plasma (normal range 70–130%).
HAE therapies aim to treat and prevent the signs and
symptoms of HAE, especially its disabling and life-
threatening attacks. Routine prophylactic administration of
exogenous C1-INH has been shown to be safe and clinically
effective for the prevention of attacks, and are recommended
to restore and maintain C1-INH functional activity (C1-
INH(f)).3,4 Until recently, the established dose regimen for
routine prevention of attacks was twice-weekly i.v. infusion of
1,000 IU C1-INH. Subcutaneous C1-inhibitor (HAEGARDA;
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CSL Behring, Marburg, Germany), recently approved by the
US Food and Drug Administration (FDA), remedies some of
the key limitations associated with IV administration for
patients with HAE who require long-term prophylaxis. A
phase II trial demonstrated that C1-INH (SC) dose-
dependently increased trough plasma levels of C1-INH(f)5;
the phase III Clinical Studies for Optimal Management in Pre-
venting Angioedema with Low-Volume Subcutaneous C1-
inhibitor Replacement Therapy (COMPACT) trial found that
twice-weekly C1-INH (SC) significantly reduced the fre-
quency of HAE attacks.6 To date, no single exposure–
response model has been established to quantify the
decrease in HAE attacks observed with increasing C1-
INH(f). The present analysis describes a model which, we
believe for the first time, elucidates the relationship between
C1-INH(f) levels after C1-INH (SC) administration and the
risk of experiencing an HAE attack as well as describing
subject-related factors that may influence this exposure–
response relationship.
METHODS
Study design and data source
The development of the exposure–response model utilized
data from the pivotal phase III COMPACT study, a random-
ized trial with a crossover design, in which subjects with
HAE received twice-weekly prophylactic doses of 40 IU/kg
or 60 IU/kg C1-INH (SC; CSL830) followed by placebo for
16 weeks of each treatment, or vice versa. Patients were
randomized if their HAE clinical diagnoses were confirmed
by central laboratory testing and if they experienced a pre-
determined number of HAE attacks during any consecutive
4-week period or during the first 2 weeks of the run-in
period. Further study design and details have been
reported recently and are given in the Supplementary
Materials.6 The COMPACT study received appropriate
review board approval, and patients provided written
informed consent to participate. The data for the present
analysis included dose amounts, times of dose administra-
tion, patient-specific parameters (weight and age at base-
line, gender, number of attacks, prior randomization, HAE
type (I vs. II), and observed baseline C1-INH(f)), and indi-
vidual post hoc pharmacokinetic (PK) parameters predicted
from a population pharmacokinetic (PopPK) model. The
study permitted rescue therapy (C1-INH (IV)) for the acute
treatment of HAE attacks; the PopPK analysis included
dosing information for HAE rescue therapy in cases in
which C1-INH (IV) was administered. Plasma samples for
assessment of C1-INH(f) were collected during the phase
III COMPACT study at 1,062 sampling points. The occur-
rences of HAE attacks and symptoms were recorded by
patients using e-diaries and were assessed by investi-
gators; these were logged in along with the administration
of rescue medication by the investigators at each trial visit.
Methodology of exposure–response approach
A repeated time-to-event model was used to characterize
the timing and frequency of attacks as a function of C1-
INH(f).7,8 Parametric model development assessed three
main components; a background effect, a nondrug effect
(e.g., time effect), and a C1-INH (SC) effect, which allowed
for informative use of the changes in C1-INH(f).
Exploratory exposure–response evaluation for risk of
attacks
A PopPK analysis was performed using data from the
phase I to phase III clinical studies of treatment with C1-
INH (IV) or C1-INH (SC; total 2,103 samples).5,6 The C1-
INH(f) following administration of C1-INH (SC) was
adequately described by a linear one-compartment model
with first-order absorption and first-order elimination, with
interindividual variability on all the parameters. The PopPK
model found body weight to be a significant covariate on
clearance. The parameters were estimated with good preci-
sion and shrinkage. Goodness-of-fit criteria revealed no
indication of any substantive deficiency in the ability of the
final model to characterize the trend and variability in the
observed PK data. The results of the PopPK model will be
published separately.
The subject-specific PK parameters obtained from the
PopPK analysis were used to predict the individual C1-
INH(f) time profiles following administration of C1-INH (SC).
These time profiles were used to inform the exposure–
response analysis; the PK model predictions of C1-INH(f)
at the time of the attack following C1-INH (SC) exposure
were directly linked to the timing and frequency of the
attack using the repeated time-to-event hazard model, as
seen in Figure 1.
The timing (clock time) of an attack on a particular day was
not available, therefore, events were treated as interval-
censored based upon the calendar day. More formally, let T
be a random variable representing the time of an HAE attack
based on continuous time and relative to the first dose of
study medication or the end of a previous HAE attack, which-
ever is later. Let D be the ending time of the day on which
a new event occurs. From the construction, D-1<TD and
D-1, D defines the censoring interval. This interval will be 24
hours as related to the calendar day, except if an event
occurs on the calendar day corresponding to the first dose of
study medication. In this case, the interval duration is defined
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Figure 1 Absolute risk of a breakthrough hereditary angioedema
(HAE) attack vs. C1-esterase inhibitor functional activity (C1-
INH(f)) (%). Blue dots represent the model predicted hazard vs.
C1-INH(f) (%) in each patient.
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from the first dose of study medication to the end of the cal-
endar day (<24 hours). Let W represent the time corre-
sponding to the end of the study or subject withdrawal. W is
also defined relative to the first dose of study medication or
the end of a previous HAE attack, similar to D. The interval-
censored probability of an event and the right-censored prob-
ability of not observing an event before withdrawal are:
Event : Pr D21 < T  Dð Þ5S D21ð Þ2S Dð Þ
Censored : Pr T > Wð Þ5S Wð Þ (1)
where Pr(•) represents a probability; and S(•) represents
the survival function. The survival function is related to the
hazard, used in the exposure–response modeling, by the
following equation:
S tð Þ5P T > tð Þ5e
2
Ðt
0
h mð Þdm
(2)
where h is the hazard function and m is the (time) variable
of integration.
When an HAE attack occurred, the risk of having another
attack (S(t)) was not allowed to accrue until after the attack
resolved; effectively, the subject was removed from the risk
set. Despite the subject not being at risk of an event, the
dose of rescue medication was included in the PK compo-
nent of the exposure–response model as the rescue medi-
cation is an IV formulation of the treatment. The PK
information following rescue were needed to ensure proper
prediction of C1-INH exposure throughout the time course
of a subject. After each HAE attack resolved, the accumula-
tion of risk over time was reinitiated and related to C1-
INH(f). Overall, the strategy of interval censoring was used
to avoid assumptions about when the attack occurred, yet it
kept as much resolution in the timing of the event in order
to best associate it with C1-INH(f) fluctuations.
A general parametric model was assessed in order to
characterize the log hazard function, where fb, fnd, and fd
represent the baseline, nondrug (e.g., time effects), and
drug functions, respectively, t represents (continuous) time,
which is relative to the first dose of study medication
(t50):
log h tð Þ5fb1fnd tð Þ1fd t ;Cp
 
(3)
A standard baseline parameterization was used for fb (i.e.,
a fixed (B0) and additive random effect), and g (defined as
fb5B01 g). Linear, power, or exponential plateau functions
in time were tested for the nondrug functions, fnd. Linear,
power, maximum effect (Emax) or sigmoidal Emax functions
were evaluated for the C1-INH (SC) drug effect function, fd,
where Cp represents model-predicted C1-INH(f) at time T.
Interindividual variability was considered for the time-to-
event model through g to account for correlation between
repeated events within the subject and heterogeneity
between individuals. The “g”s were assumed to be normally
distributed with mean 0 and variance x2.
Alternative methods that were evaluated included the
importance sampling expectation maximum and stochastic
approximation expectation maximum because the Laplace
approximation often failed to converge during estimation
when evaluating covariates.
Covariate evaluation
Covariates evaluated in the analysis were: body weight,
age, gender, observed baseline C1-INH(f), baseline HAE
attack counts, and HAE type (I vs. II). Clinical judgment
was used to determine which covariates were tested on
which parameters.
The full model with backward elimination approach was
specified originally for covariate model selection. Due to the
long run-times for each model and some unreasonable
covariate effect estimates (likely due to confounding), back-
ward elimination was used to pare down the full model to a
working full model that did not have the unreasonable esti-
mates. Next, the Wald’s approximation method9 was used
with the working full time-to-event model to identify a subset
of reduced time-to-event models. Given that the Wald’s
approximation method does not require full nonlinear
mixed-effect modeling (NONMEM) estimation for each step
means that this approach is computationally economical for
models with long run-times.
The Wald’s approximation method procedure used a pen-
alty of 10.83 (based on a v2 distribution with 1 degree of
freedom at P5 0.001) to rank the subset of reduced time-
to-event models. The ranks for the Wald’s approximation
method and NONMEM-verified results were compared for
selection of the final exposure–response model. Moreover,
where significant covariate effects were identified, the mag-
nitudes of the effects over relevant ranges, along with 95%
confidence intervals, were provided.
Model evaluation
A visual predictive check, specifically a graphical posterior
predictive check, was performed using the final model.
Uncertainty in the population parameters was not incorpo-
rated. Therefore, the visual predictive check was conserva-
tive, in that the prediction intervals computed were smaller
than the nominal value achieved had uncertainty been
incorporated. The visual predictive check was conducted to
align with the clinical evaluation of efficacy, which was con-
cerned with the distribution of attacks, and was performed
by comparing observed and predicted cumulative probabili-
ties of the HAE attack rate, time-normalized by month. The
visual predictive check was computed by treatment group,
40 or 60 IU/kg C1-INH (SC) or placebo. The random effects
g were sampled for the visual predictive check.
To generate the visual predictive check, the HAE attack
data were simulated from the model, conditional on individ-
ually predicted PK concentration-time profiles. The cumula-
tive hazard was computed by day as a function of
C1-INH(f), and itself was used to compute survival function
values for each day, from which the probability that an
event occurred was derived. Specifically, a uniformly distrib-
uted random number u* was sampled (u*U(0,1)), and 1-
u* was compared to S(D-1) and S(D), where S(•) is the sur-
vival function and D represents the time since the first dose
of study medication or resolution of a previous HAE attack
in days. If S(D)1–u* <S(D-1), then an event was
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registered on day D. Following an event, the risk of a new
event (starting at 0) was allowed to accrue, and a new u*
was sampled. The occurrence of a simulated event was
also evaluated. This process was repeated until the end of
the study or withdrawal.
Simulations
The final model was used to simulate the absolute hazard
of attacks over a wide range of C1-INH(f) values (20–
120%). The hazard ratio was computed using the geometric
mean of observed baseline C1-INH(f) as the reference
(25.4%), compared to C1-INH(f) ranging from 25.4–120%.
RESULTS
Study population
Ninety subjects from the phase III COMPACT study experi-
enced 1,191 attacks and 234 censored events. Baseline
characteristics and demographics for the study population
are summarized in Table 1. All subjects who were adminis-
tered at least one dose of placebo or C1-INH (SC) were
included in the analysis.
Model findings
The parametric model described above was evaluated
using the HAE data. These data did not support drug-
independent changes in the hazard over time; therefore,
the nondrug component of the model was excluded. The
model included a constant baseline hazard plus an Emax
model to relate C1-INH(f) concentration to the instanta-
neous risk of an event.
Covariate effects were evaluated using the Wald’s approxi-
mation method. The top five models from the Wald’s approxi-
mation method and the top three from the NONMEM-based
evaluation are reported in Supplementary Table S1. The
final exposure–response model (run 1) included the covari-
ate age on B0 but eliminated the other covariates, such as
body weight, gender, observed baseline C1-INH(f), baseline
HAE attack counts, and HAE type (I vs II) on B0 and Emax,
resulting in an increase of the objective function value of 27
units (compared to the working full model). The final time-to-
event model for describing the absolute hazard of a break-
through HAE attack in subjects receiving C1-INH (SC)
therefore is:
h tð Þ5exp 0:08ð Þ  age=42ð Þ1:05  exp 210:5ð Þ  Cp= exp 3:4ð Þ1Cp
  
(4)
Based on the final model parameters (including the random
effect on B0), the exposure–response relationship (absolute
risk of a breakthrough HAE attack vs. predicted C1-INH(f);
%) was derived (Figure 1). The relationship between abso-
lute attack risk relative to C1-INH(f) exemplified that,
although the baseline risk of an HAE attack varies as a
function of age, there is no difference in the effect of C1-
INH (SC; i.e., in terms of half-maximal effective concentra-
tion (EC50) and Emax). The parameters of this time-to-event
model are presented in Table 2.
Covariate evaluation
Covariates evaluated in the analysis were: body weight,
age, gender, observed baseline C1-INH(f), baseline HAE
attack counts, and HAE type (I vs. II). Clinical judgment
was used to determine which covariates were tested on
which parameters. Continuous covariates were centered at
their typical values (TVCOV) and the typical value for param-
eters (TVP) expressed as:
TVp5hP1hCOV ;P log COVið Þ2log TVCOVð Þð Þ (5)
where hP was the estimated parameter representing the
model parameter P when the individual covariate (COVi)
was equal to TVCOV, and hCOV,P was the estimated
Table 1 Subject characteristics and demographics
Covariate
Statistic or
category
Phase III
COMPACT study
Total number 90
Age at baseline, years Median [min–max] 40.0 [12–72]
Weight at baseline, kg Median [min–max] 78.1 [43–157]
Observed baseline
C1-INH(f), %
Median [min–max]
Geometric mean (SD)
25 [4.5–77]
25.4 (1.67)
Baseline (historical HAE
attack in run-in period,
no. of patients)
Median [min–max] 3 [0–11]
Gender, no. of patients Male
Female
30
60
HAE type, no. of patients Type 1
Type 2
78
12
Total breakthrough HAE
attack, no. of patients
1,425
C1-INH(f), C1-inhibitor functional activity; COMPACT, Clinical Studies for
Optimal Management in Preventing Angioedema with Low-Volume Subcuta-
neous C1-inhibitor Replacement Therapy; HAE, hereditary angioedema.
Table 2 Parameter estimates of final C1-INH (SC) population time-to-event model
Parameter estimate [units] Point estimate SE 95% CIa Derived parameter [units]b
B0 [hazard]
c 0.0802 0.380 20.665 to 0.825 1.08 [hazard]
Age, years on B0 1.05 0.254 0.552–1.55 –
Emax, maximum effect 210.5 0.334 211.2 to 29.84 0.99 [maximum fractional reduction in risk]
EC50, % 3.40 0.123 3.16–3.64 29.9 [C1-INH(f) %]
Interindividual variance
XB0 0.871 0.15 – –
C1-INH, C1-inhibitor; C1-INH(f), C1-inhibitor functional activity; CI, confidence interval; EC50, half-maximal effective concentration; Emax, maximum effect.
a95% CI calculated estimate6 1.96 3 SE. Derived parameters were calculated as exp (estimate). bParameters were derived as follows: B05 exp
Parameter Esti-
mate; Emax was calculated as 1-exp
(ParameterEstimate); EC505 exp
Parameter Estimate. cThe shrinkage estimate for B0 was 6.0%.
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parameter representing the influence of continuous covari-
ates on model parameter P.
Categorical covariates were tested and incorporated in
the model as a series of indicator variables taking on val-
ues of zero or one. The variables were included in the
model as follows:
TVp5hP1hCAT ;P3CATi (6)
where TVP was as previously defined and hCAT,P was the
estimated parameter representing the influence of categori-
cal covariates on model parameter P.
Predictive performance
The relationship between the cumulative probability of an
HAE attack per month with C1-INH (SC) dose rate (pla-
cebo, 40 IU/kg, and 60 IU/kg), based on 500 simulations is
shown in Figure 2. The visual predictive check indicated
that the predictions intervals (shaded regions) of the model
generally contained the observed values (lines). There is
some potential for lack of perfect fit by the model as noted
by the visual predictive check; the model may underpredict
the higher HAE attack frequency for the placebo and treat-
ment groups. Overall, the predictive performance of the
final model was considered adequate for characterizing the
exposure–response relationship.
Figure 2 The relationship between cumulative probability of a breakthrough hereditary angioedema (HAE) attack and time of normal-
ized attacks per month. The solid blue and green lines represent the cumulative probability of the observed HAE attacks (normalized
by month). The blue and green bands reflect the 90% prediction intervals (without uncertainty based on estimation) based on 500 sim-
ulations based on the final model. C1-INH, C1-esterase inhibitor.
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Figure 3 Predicted absolute risk of an hereditary angioedema (HAE) attack vs. C1-esterase inhibitor functional activity (C1-INH(f)) (%)
stratified by age. The blue solid line represents the absolute risk of HAE attack at the median age (40 years old) of the patient popula-
tion in the study. The blue dotted lines represented the 5th and 95th (20–60 years old) confidence interval of the age of the patient
population in the study.
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Simulations
The mean absolute risk of an attack varied across a wide
range of C1-INH(f) (20–120%), demonstrating a strong
exposure–response relationship between the risk of a
breakthrough HAE attack and C1-INH(f). In order to assess
the effect of age on the baseline risk of an HAE attack, the
absolute risk across a range of C1-INH functional activities
(20–120%) was simulated at ages 20, 40, and 60 years for
the typical individual (g5 0; Figure 3). These ages corre-
sponded to the 5th, 50th, and 95th percentiles of the sub-
ject population in the phase III COMPACT study.
In the phase III COMPACT study, the observed geometric
mean baseline C1-INH(f) was 25.4%.6 This was considered
to be the C1-INH(f) with no treatment and was used as the
reference C1-INH(f) value (Cr) to assess the relative reduc-
tion in rate of HAE attacks using the following equation:
Hazard ratio h tð Þ5 e
210:53Cp
e3:41Cp
e
210:53Cr
e3:41Cr
(7)
Figure 4 shows the relative risk of a breakthrough HAE
attack across a wide range of C1-INH(f) activities for trough
concentration, Cp. The figure also shows the C1-INH(f) (%)
thresholds that would result in a 50%, 70%, and 90%
reduction in risk of an HAE attack, whereas on treatment
with C1-INH (SC) compared to baseline C1-INH(f) levels
(i.e., no C1-INH (SC) prophylaxis given). The model esti-
mated that 50%, 70%, and 90% reductions in relative risk
corresponded to C1-INH(f) values of 33.1%, 40.3%, and
63.1%, respectively.
To understand the proportion of an HAE population that
which would be expected to exceed these desired levels of
C1-INH(f) at a given dose, steady-state C1-INH functional
activities for 1,000 subjects with HAE dosed with 40 IU/kg
and 60 IU/kg C1-INH (SC) were simulated using the final
population PK model. The proportion of HAE subjects
expected to have C1-INH(f) levels greater than the levels
related to a relative risk reduction (50%, 70%, and 90%)
were derived for C1-INH (SC) doses of 40 IU/kg and 60 IU/
kg (Figure 4). Based on the simulations, Ctrough levels of
40.2% would be obtained at 40 IU/kg C1-INH (SC) and
48.0% at 60 IU/kg C1-INH (SC). At the 40 IU/kg dose,
50.0% of patients with HAE were estimated to experience a
70% reduction in the risk of an HAE attack when com-
pared to no prophylaxis. At the 60 IU/kg dose, 67% of
patients with HAE were estimated to experience a 70%
reduction in relative risk. Overall, the 40 IU/kg and 60 IU/kg
doses may both achieve 50% reductions in the relative
risk of an HAE attack in over 72% of subjects. The differ-
ence between the two doses was most pronounced at the
90% reduction in relative risk of an HAE attack. The
reduction in relative risk of an HAE attack was always
greater in a higher percentage of subjects with the 60 IU/kg
dose (Table 3).
DISCUSSION
A subcutaneous formulation of C1-INH (CSL830), which
was recently approved by the FDA, offers a new option for
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Figure 4 Simulated relationship between the relative risk of a breakthrough hereditary angioedema (HAE) attack and C1-esterase
inhibitor functional activity (C1-INH(f); relative to the geometric mean baseline C1-INH(f) of 25.4%) with predicted Ctrough values
expected after administering C1-esterase inhibitor (C1-INH (SC)). Box plots represent the range of observed baseline C1-INH(f) values
(baseline) and steady-state final population pharmacokinetic model-predicted Ctrough after 40 IU/kg and 60 IU/kg doses of C1-INH
(SC), respectively. Black lines within the box represent the median value, the red circle represents the geometric mean, and these
numbers are listed above the box. The red dashed line is the median of the simulation. The pink shaded area represents the prediction
intervals (SEs in the parameter estimates only). The blacked dashed lines represent 50%, 70%, and 90% reductions in relative risk of
a breakthrough HAE attack. Longhurst, H.J. et al.6 Prevention of hereditary angioedema attacks with subcutaneous C1 inhibitor.
N. Engl. J. Med. 376, 1131–1140 (2017). Copyright VC 2017 Massachusetts Medical Society. Reprinted with permission from Massachu-
setts Medical Society.
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routine prevention of HAE attacks in adolescents and
adults. In the phase III COMPACT trial, patients who
received twice-weekly prophylactic doses of 40 IU/kg and
60 IU/kg C1-INH (SC) experienced significantly fewer HAE
attacks than patients who received placebo (P< 0.001 for
both comparisons). Overall, HAE attack rates were reduced
by a median of 89% for the 40 IU/kg and by 95% for the 60
IU/kg dose.6
It was previously suggested that a critical level for C1-
INH(f), below which patients with HAE were more likely to
experience HAE attacks, was at 40% of normal C1-
INH(f); however, this was based on the relationship
between C1-INH antigen and apparent function.10 As yet,
the relationship between C1-INH(f) levels and the risk of
HAE attacks has not been evaluated. The present analysis,
using phase III COMPACT data, aimed to develop an
exposure–response model quantifying the relationship
between C1-INH(f) and attack risk, and to identify patient
factors that may influence this relationship.
This analysis substantiates the phase III COMPACT
study results and supports the prophylactic use of C1-INH
(SC) in patients with HAE. First, our interval-censored
Emax-based time-to-event model adequately described the
relationship between plasma C1-INH(f) and the frequency
and timing of HAE attacks, such that higher C1-INH func-
tional activities corresponded to greater reductions in attack
risk. Second, covariate testing in the exposure–response
model revealed an effect of age on the baseline risk of
experiencing an attack; the prophylactic effect of C1-INH
(SC) was, however, independent of age. Other covariates
tested, including body weight, gender, observed baseline
C1-INH(f), baseline HAE attack counts, and HAE type (I vs.
II), did not demonstrate a major influence on the baseline
risk of having an HAE attack or the effect of C1-INH (SC)
treatment. Third, administration of either the 40 IU/kg or
60 IU/kg dose resulted in 50% reductions in the relative
attack risk in the majority of subjects, with the risk reduction
greater in a higher percentage of subjects treated with the
60 IU/kg dose. Fourth, the findings of this analysis corrobo-
rate the previously suggested critical level of 40% for C1-
INH(f), below which patients with HAE are more likely to
experience HAE attacks.10
Based on this model, the maintenance of higher steady-
state values of C1-INH(f) would provide greater preventive
effect, thus significantly decreasing the risk of experiencing
an HAE attack compared to no treatment. This analysis
also revealed the potential for further optimization of dosing
that may provide almost complete protection against HAE
attacks through the use of the exposure–response model.
This model may also be used to compare various dosing
regimens and routes of administration. The model may be
further explored for its utility in individualized dosing to
achieve improved attack protection.
To the best of our knowledge, the present analysis is the
first attempt to quantify the relationship between the risk of
HAE attacks and C1-INH(f) after replacement therapy.
Unlike traditional methods of logistic and linear regression,
time-to-event models, such as those used in this analysis,
naturally encompass both the frequency and timing of
events.11 Interval censoring was used because the event
timing during the day was unknown; this censoring avoided
assumptions about imputing the event time and also the PK
parameter driving the relationship (such as trough plasma
concentration (Cmin) or average concentration (Cavg)). The
effect of C1-INH(f) was applied to the instantaneous risk of
an event, and this risk was integrated over the day to deter-
mine the probability that an HAE attack occurred. The pre-
dictive performance of the final model was evaluated by
applying a visual predictive check to assess how closely
model simulations replicated the cumulative distribution of
the frequency of breakthrough attacks normalized by month
(the primary endpoint of the study). The interpretation of
this approach differs from the selection of a PK driver that
may or may not be verified, given that the exact event times
were not known.
The visual predictive check did not account for the drop-
out rate; however, it should be noted that this rate was
minor and not linked to HAE attacks. Lack of perfect fit may
be due to linking the risk of HAE attack directly to plasma
C1-INH(f). HAE is a local disease, such that events occur
peripherally, and, thus, risk may be related more to C1-INH
levels in different tissues of the body. It should be noted
that the model provides a conservative estimate—it over-
predicts the distribution of larger numbers of HAE attack
counts, thus, to some extent, understating the full potential
of C1-INH treatment. As such, the Emax relationship
between risk and plasma concentration may only approxi-
mate the true relationship between risk and overall C1-INH
exposure. Nevertheless, by assessing general aggregate
risk for HAE attacks in relation to target and actionable
plasma C1-INH(f) exposures, we established that plasma
C1-INH concentration can sufficiently predict attack risk so
as to provide guidance for informing dosage regimens that
will be useful to patients with HAE.
In conclusion, we describe an interval-censored repeated
time-to-event model able to characterize the exposure–
response relationship between C1-INH(f) and the risk of
breakthrough HAE attacks. The defined exposure–response
relationship confirmed that a greater reduction in the rela-
tive risk of an HAE attack correlates with increasing C1-INH
functional activities.
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